Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

Similar articles for PubMed (Select 23671391)


Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer.

Wu Q, Shi Y, Chen L, Xiao X, Dai G.

Onco Targets Ther. 2013 Apr 30;6:485-90. doi: 10.2147/OTT.S41449. Print 2013.


Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.


A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.

Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H.

Onco Targets Ther. 2014 Jul 1;7:1177-84. doi: 10.2147/OTT.S63739. eCollection 2014.


A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer.

Wang G, Ye Y, Zhang X, Liu H, Song J.

Med Oncol. 2015 May;32(5):566. doi: 10.1007/s12032-015-0566-2. Epub 2015 Apr 22.


The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.


Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T.

Springerplus. 2013 Apr 25;2(1):185. doi: 10.1186/2193-1801-2-185. Print 2013 Dec.


Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.

Zhu LM, Zhao YZ, Ju HX, Liu LY, Chen L, Liu BX, Xu Q, Luo C, Ying JE, Yang YS, Zhong HJ.

Asian Pac J Cancer Prev. 2014;15(16):6559-64.


XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.

Duran AO, Karaca H, Besiroglu M, Bayoglu IV, Menekse S, Yapici HS, Yazilitas D, Bahceci A, Uysal M, Sevinc A, Hacibekiroglu I, Aksoy A, Tanriverdi O, Arpaci E, Inanc M, Dane F, Ozkan M.

Asian Pac J Cancer Prev. 2014;15(23):10375-9.


XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI.

Suzuki K, Takaharu K, Muto Y, Ichida K, Fukui T, Takayama Y, Tsujinaka S, Sasaki J, Horie H, Kawamura YJ, Konishi F, Rikiyama T.

Mol Clin Oncol. 2014 Sep;2(5):827-832. Epub 2014 Jun 6.


Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment.

Bai L, Zhang DS, Wu WJ, Ren C, Wang DS, Wang F, Qiu MZ, Xu RH.

Med Oncol. 2015 Feb;32(2):469. doi: 10.1007/s12032-014-0469-7. Epub 2015 Jan 13.


Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer.

Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R.

Mol Clin Oncol. 2014 Jan;2(1):166-170. Epub 2013 Nov 12.


Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.

Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D.

Acta Oncol. 2015 Feb;54(2):171-8. doi: 10.3109/0284186X.2014.961649. Epub 2014 Oct 13.


Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer.

Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L.

Onco Targets Ther. 2014 Aug 11;7:1415-22. doi: 10.2147/OTT.S64559. eCollection 2014.


Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.

Mineur L, Sabatier R, Kirscher S, Plat F, Goubely Y, Molinari N.

Clin Res Hepatol Gastroenterol. 2011 Feb;35(2):125-31. doi: 10.1016/j.gcb.2009.11.005. Epub 2010 Nov 25.


Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.

Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A; ARIES Study Investigators.

Clin Oncol (R Coll Radiol). 2014 Jun;26(6):323-32. doi: 10.1016/j.clon.2014.03.001. Epub 2014 Mar 28.


The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.

Hammerman A, Greenberg-Dotan S, Battat E, Feldhamer I, Bitterman H, Brenner B.

Acta Oncol. 2015 Feb;54(2):164-70. doi: 10.3109/0284186X.2014.958532. Epub 2014 Oct 28.


Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; BEBYP Study Investigators.

Ann Oncol. 2015 Apr;26(4):724-30. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.


Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation.

Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P, Romiti A, Barucca V, Giannini G, Bianchi L, Tomao S.

Onco Targets Ther. 2013 Nov 29;6:1761-9. doi: 10.2147/OTT.S43828. eCollection 2013.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk